The TANGO trial demonstrated the efficacy of lamivudine plus dolutegravir in virologically suppressed patients without previous virological failures (VFs). In this dataset from clinical practice investigating the impact of past nucleoside reverse-transcriptase inhibitor resistance on this strategy, the combination of M184V/I plus at least 1 thymidine analog-associated mutation significantly increased the risk of VF.
|Journal||Open Forum Infectious Diseases|
|Publication status||Published - Jul 2021|
- maintenance therapy
- resistance-associated mutations
ASJC Scopus subject areas
- Clinical Neurology